These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
121 related items for PubMed ID: 10622674
1. Assessing the societal impact of acetylcholinesterase inhibitor therapies. Winblad B, Wimo A. Alzheimer Dis Assoc Disord; 1999 Nov; 13 Suppl 2():S9-19. PubMed ID: 10622674 [Abstract] [Full Text] [Related]
3. Determinants of costs of care for patients with Alzheimer's disease. Jönsson L, Eriksdotter Jönhagen M, Kilander L, Soininen H, Hallikainen M, Waldemar G, Nygaard H, Andreasen N, Winblad B, Wimo A. Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288 [Abstract] [Full Text] [Related]
4. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. Lu S, Hill J, Fillit H. Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386 [Abstract] [Full Text] [Related]
5. [Caregiver burden in relatives of persons with schizophrenia: an overview of measure instruments]. Reine G, Lancon C, Simeoni MC, Duplan S, Auquier P. Encephale; 2003 Jun; 29(2):137-47. PubMed ID: 14567165 [Abstract] [Full Text] [Related]
6. Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors. Versijpt J. Acta Neurol Belg; 2012 Jun; 112(2):141-5. PubMed ID: 22476975 [Abstract] [Full Text] [Related]
8. [Predictors of long-term institutionalization in patients with Alzheimer's disease: role of caregiver burden]. Hirono N, Tsukamoto N, Inoue M, Moriwaki Y, Mori E. No To Shinkei; 2002 Sep; 54(9):812-8. PubMed ID: 12428367 [Abstract] [Full Text] [Related]
9. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Rice DP, Fillit HM, Max W, Knopman DS, Lloyd JR, Duttagupta S. Am J Manag Care; 2001 Aug; 7(8):809-18. PubMed ID: 11519239 [Abstract] [Full Text] [Related]
10. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, Oliva-Moreno J. Neurology; 2006 Dec 26; 67(12):2186-91. PubMed ID: 17190942 [Abstract] [Full Text] [Related]
11. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease. Marin D, Amaya K, Casciano R, Puder KL, Casciano J, Chang S, Snyder EH, Cheng I, Cuccia AJ. Int Psychogeriatr; 2003 Dec 26; 15(4):385-98. PubMed ID: 15000418 [Abstract] [Full Text] [Related]
13. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Jönsson L. Am J Geriatr Pharmacother; 2005 Jun 26; 3(2):77-86. PubMed ID: 16129384 [Abstract] [Full Text] [Related]